Small molecule alliance
Turku – Finland’s Faron Pharmaceuticals Ltd. has announced a cooperation with German biotech company Priaxon AG to create new scaffold structures to modify the AOC3-protein function and its ligand interaction with orally available drugs. ”AOC3 and its enzymatic domain SSAO play a central role in many chronic inflammatory conditions that could lead to deterioration of vasculature and key organs,” said Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals. Using Priaxon’s technology for uncovering small molecule therapeutics from a pre-encoded chemical reaction library, the Finnish company wants to further develop its drug programmes, focusing on acute traumas, incipient vasculopathies, inflammatory diseases, and cancer/metastasis growth. Faron’s lead product is in a Phase I/II study to treat vascular leakage in ALI/ARDS patients.